New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 1, 2013
09:17 EDTLXRX, BTN, WAG, AIXG, MYGN, RH, MRK, PSTI, EDGOn The Fly: Pre-market Movers
HIGHER: Merck (MRK), up 3% after announcing restructuring plans, including intent to cut about 20% of workforce by end 2015... Lexicon (LXRX), up 21% after achieving positive clinical trial results for potential diabetes drug... Edgen Group (EDG), up 57% after agreeing to be acquired by Sumitomo Corp. for $12.00 per share... Myriad Genetics (MYGN), up 11% after Piper Jaffray says should be bought on any weakness and stock upgraded at Ladenburg... Ballantyne Strong (BTN), up 6% after acquiring Convergent Media Systems... Pluristem (PSTI), up 5% after PLX cells demonstrate efficacy in preclinical study for GvHD. LOWER: Walgreens (WAG), down 0.5% after Q4 earnings report... Aixtron (AIXG), down 4% after downgrade at Canaccord... Restoration Hardware (RH), down 3% after holder CP Home files to sell about 4M shares.
News For MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:52 EDTMRKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:22 EDTMRKMerck receives positive CHMP opinion for Pembrolizumab in advanced melanoma
Subscribe for More Information
07:15 EDTMRKMerck receives positive CHMP opinion for KEYTRUDA in advanced melanoma
Merck announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma, as both first-line therapy and in previously treated patients. The CHMP positive opinion for KEYTRUDA, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union.
May 19, 2015
07:28 EDTMRKUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTMRKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
09:25 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
08:33 EDTRHRestoration Hardware names Sanchak as Chief Real Estate & Development Officer
Restoration Hardware announced that David Stanchak has joined the Company as Chief Real Estate and Development Officer, effective immediately. In this newly created position, Stanchak will be leading the transformation of RH’s current legacy galleries into next generation Design Galleries, with responsibility for the company’s real estate and store development efforts. Stanchak will report to RH’s Chairman and CEO, Gary Friedman, and serve as a member of the company’s Executive Leadership team.
05:13 EDTPSTIPluristem PLX Cells selected for EMA adaptive pathways pilot project
Subscribe for More Information
May 15, 2015
10:28 EDTMYGNMAC updates positive for NanoString, Myriad, Invitae, QIAGEN, says Leerink
Leerink said that coverage updates posted yesterday by Medicare Administrative Contractors were favorable for NanoString (NSTG), Myriad Genetics (MYGN), Invitae (NVTA) and QIAGEN (QGEN). The firm has Outperform ratings on NanoString and Invitae and Market Perform rating on the other two stocks listed.
07:09 EDTMYGNMyriad Genetics presents clinical data for Prolaris test
Myriad Genetics presented clinical data for its Prolaris test at the 2015 American Urological Association, or AUA, Annual Meeting being held May 15-19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians improve care for men diagnosed with prostate cancer. In this pioneering study, Myriad presented important new clinical validation data that establishes an active surveillance, or AS, threshold for men with localized prostate cancer. Specifically, the AS threshold is a composite of the Prolaris test score and clinicopathologic features. In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality. The results showed that at the AS threshold, the predicted 10-year survival rate of prostate cancer patients was 97%. Conversely, there was a three percent risk of 10-year, prostate-specific mortality. Importantly, however, there were no observed prostate cancer-specific deaths over 10 years among men whose scores fell below the AS threshold. Additionally, a separate analysis of 4,218 patients was performed to determine what percentage of patients who were clinically tested with Prolaris would be candidates for active surveillance based on the validated AS threshold. Of this commercial cohort, 36% qualified for active surveillance based on their clinical features alone. However, when the Prolaris test was added to the clinical risk assessment, 60% of these patients fell below the AS threshold, representing a significant increase in the total number of candidates who may be eligible for active surveillance.
May 14, 2015
09:22 EDTMRKLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
May 13, 2015
18:47 EDTMYGNMyriad Genetics to present data from 19 studies at 2015 ASCO meeting
Subscribe for More Information
18:33 EDTMRKMerck to present new Keytruda data on 10 types of cancer at 2015 ASCO meeting
Subscribe for More Information
13:12 EDTMRKSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
05:43 EDTPSTIPluristem announces PMDA quality approval for PLX-PAD cells for use in trial
Subscribe for More Information
May 12, 2015
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
May 11, 2015
18:29 EDTMYGNAffordable Care Act guidance says insurers must cover BRCA1, BRCA2 testing
The United States Department of Labor issued updated Affordable Care Act guidance, which mandates that health insurers must cover testing for breast and ovarian cancer through analysis of the BRCA1 and BRCA2 genes. Myriad (MYGN), Foundation Medicine (FMI), and Genomic Health (GHDX) compete in the genetic testing space. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use